Therefore, it is worth exploring whether the effect of SGLT2 inhibitors on blood lipid levels in type 2 diabetes mellitus patients is related to the dosages of SGLT2 inhibitors and the degree of correlation. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.